EUVIMEDEUVIMED entdecken
Multizentrische Studie

Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image–Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study

Maximilian P Schmid iD, Jacob C Lindegaard iD, Umesh Mahantshetty, Kari Tanderup, Ina Jürgenliemk-Schulz, Christine Haie-Meder, Lars U Fokdal, Alina Sturdza, Peter Hoskin iD, Barbara Segedin, Kjersti Bruheim, Fleur Huang iD und 19 weitere

Journal of Clinical Oncology · 2023

DOI: 10.1200/jco.22.01096 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Maximilian P Schmid und 30 weiteren Autor:innen. Beteiligte Einrichtung: Medical University of Vienna, Department of Radiation Oncology- Comprehensive Cancer Center, Vienna, Austria. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Brachytherapy, Radiotherapy, Image-Guided. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Austrian Science Fund FWF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To report clinical and treatment characteristics, remission and failure patterns, and risk factors for local failure (LF) from the EMBRACE-I study. MATERIALS AND METHODS EMBRACE-I was a prospective, observational, multicenter cohort study on magnetic resonance imaging–based image-guided adaptive brachytherapy (MR-IGABT) in locally advanced cervical cancer. Treatment consisted of external beam radiotherapy, concurrent chemotherapy, and MR-IGABT. LF was defined as progressive or recurrent disease in the cervix, uterus, parametria, pelvic wall, or vagina. Competing risk analysis was used to estimate local tumor control (LC) and Cox proportional regression models for multivariable analysis and dose-response analysis. RESULTS One thousand three hundred eighteen patients with a median follow-up of 52 months were available for this analysis. Eighty-one patients had persistent disease 3 months after end of treatment. Of those, 60 patients achieved LC at 6-9 months without further treatment, whereas 21 patients had progressive disease. In addition, 77 patients developed a local recurrence after complete remission comprising a total number of 98 LFs. LFs were located inside the MR-IGABT target volumes in 90% of patients with LF. In multivariable analysis, histology, minimal dose to 90% of high-risk clinical target volume (CTV HR ), maximum tumor dimension, CTV HR > 45 cm 3 , overall treatment time, tumor necrosis on magnetic resonance imaging at diagnosis, uterine corpus infiltration at diagnosis and at MR-IGABT, and mesorectal infiltration at MR-IGABT had significant impact on LF. Dose-response analysis showed that a minimal dose to 90% of 85 Gy to the CTV HR led to 95% (95% CI, 94 to 97) LC 3 years postintervention for squamous cell in comparison to 86% (95% CI, 81 to 90) for adeno/adenosquamous carcinoma histology. CONCLUSION The present study demonstrates the safety and validity of the GYN GEC-ESTRO/ICRU-89 target concept and provides large-scale evidence for dose prescription and new risk factors for LF in MR-IGABT in locally advanced cervical cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsBrachytherapyRadiotherapy, Image-GuidedFemaleHumansProspective StudiesCohort StudiesNeoplasm StagingMagnetic Resonance ImagingRadiotherapy DosageRisk Factors

Autor:innen und Institutionen

  • Medical University of Vienna, Department of Radiation Oncology- Comprehensive Cancer Center, Vienna, Austria.
  • Aarhus University Hospital, Department of Oncology, Aarhus, Denmark.
  • Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai and Homi Bhabha Cancer Hospital & Research Centre, Visakhapatnam, India.
  • University Medical Centre Utrecht, Department of Radiation Oncology, Utrecht, the Netherlands.
  • Gustave-Roussy, Department of Radiotherapy, Villejuif, France.
  • Mount Vernon Cancer Centre, Northwood, United Kingdom.

ORCID-Profile: Maximilian P Schmid, Jacob C Lindegaard, Peter Hoskin, Fleur Huang, Bhavana Rai, Bradley R Pieters, Primoz Petric, Robin Ristl, Rohini Hawaldar, Kathrin Kirchheiner, Li Tee Tan

Förderung

  • Austrian Science Fund FWF

Zitieren

APA

Schmid, M. P., Lindegaard, J. C., Mahantshetty, U., Tanderup, K., Jürgenliemk-Schulz, I., Haie-Meder, C., Fokdal, L. U., Sturdza, A., Hoskin, P., Segedin, B., Bruheim, K., Huang, F., Rai, B., Cooper, R., van der Steen-Banasik, E., Van Limbergen, E., Pieters, B. R., Petric, P., Ramazanova, D., …, & EMBRACE Collaborative Group (2023). Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image–Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.01096

Vancouver

Schmid MP, Lindegaard JC, Mahantshetty U, Tanderup K, Jürgenliemk-Schulz I, Haie-Meder C, et al. Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image–Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.01096

BibTeX
@article{Schmid2023,
  author = {Schmid, Maximilian P and Lindegaard, Jacob C and Mahantshetty, Umesh and Tanderup, Kari and Jürgenliemk-Schulz, Ina and Haie-Meder, Christine and Fokdal, Lars U and Sturdza, Alina and Hoskin, Peter and Segedin, Barbara and Bruheim, Kjersti and Huang, Fleur and Rai, Bhavana and Cooper, Rachel and van der Steen-Banasik, Elzbieta and Van Limbergen, Erik and Pieters, Bradley R and Petric, Primoz and Ramazanova, Dariga and Ristl, Robin and Kannan, Sadhana and Hawaldar, Rohini and Ecker, Stefan and Kirchheiner, Kathrin and Tan, Li Tee and Nout, Remi and Nesvacil, Nicole and de Leeuw, Astrid and Pötter, Richard and Kirisits, Christian and EMBRACE Collaborative Group, EMBRACE Collaborative Group},
  title = {Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image–Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1200/jco.22.01096}
}
Kostenlos starten →